Characteristics | Presence | Presence % |
---|---|---|
Age at diagnosis (years) Median (range) | 41 (17–89) | |
≤60 | 83 | 86.5 |
>60 | 13 | 13.5 |
Gender | ||
Male | 61 | 63.5 |
Female | 35 | 36.5 |
ECOG PS | ||
0, 1 | 88 | 91.7 |
≥2 | 8 | 8.3 |
Subtypes | ||
UNKTL | 63 | 65.6 |
EUNKTL | 33 | 34.4 |
B-symptoms | 48 | 50.0 |
Mass long diameter ≥5 cm | 36 | 37.5 |
Local tumor invasion | 61 | 63.5 |
Extranodal sites ≥2 | 57 | 59.4 |
Regional lymphadenopathy | 51 | 53.1 |
Elevated serum LDH | 41 | 42.7 |
Elevated serum β2 M* | 40 | 67.8 |
Ann Arbor stage | ||
I, II | 71 | 74.0 |
III, IV | 25 | 26.0 |
IPI score | ||
0, 1 | 58 | 60.4 |
≥2 | 38 | 39.6 |
KPI score | ||
0, 1 | 49 | 51.0 |
≥2 | 47 | 49.0 |
CD30 expression | ||
Positive | 30 | 31.2 |
Negative | 66 | 68.8 |
Treatment | ||
Chemotherapy | 35 | 36.5 |
Chemotherapy + radiotherapy | 61 | 63.5 |